Staphylococcus Aureus and The Skin Microbiome During Flare And Resolution Of Atopic Dermatitis

Summary

The goal of this clinical trial is to compare and evaluate in patients with atopic dermatitis. The main questions it aims to answer are: * Does the addition of systemic dicloxacillin to TCS treatment result in a more rapid and deeper treatment response? * Does the addition of systemic dicloxacillin to TCS treatment affect the skin microbiome, the skin barrier and immune response during improvement of AD? * Does topical application of S. aureus or SEB increase the severity and rapidity of a flare? Participants will meet for two different phases: * Phase one will be at randomized controlled trial where patients are randomized to either systemic dicloxacillin + mometasone furoate or placebo + mometasone furoate. * Phase II: Patients will meet for five visits to receive different solutions on the skin including autologous s. aureus and staphylococcal enterotoxin B.

Timeline

Start

2022-10-24

Primary completion

2023-05

Completion

2023-05

Publications

• Ronnstad ATM, Bay L, Ruge IF, Halling AS, Fritz BG, Jakasa I, Luiten R, Kezic S, Thomsen SF, Bjarnsholt T, Thyssen JP. Defining the temporal relationship between the skin microbiome, immune response and skin barrier function during flare and resolution of atopic dermatitis: protocol of a Danish intervention study. BMJ Open. 2023 Feb 17;13(2):e068395. doi: 10.1136/bmjopen-2022-068395.

Drugs

Indications